11 hours Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit. Investor's Business Daily
Pfizer stock closed flat Thursday after the company pulled its sickle cell drug, Oxbryta, from the market following patient deaths.
The post Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit. appeared first on Investor's…